Talk:Factor VIII/Archive 1

Archive 1

Liposomes and PEG

doi:10.1111/j.1538-7836.2007.02856.x JFW | T@lk 07:00, 27 November 2007 (UTC)

Cerus and Baxter

CERUS AND BAXTER REPORT PRIMARY ENDPOINT MET IN U.S. PHASE III TRIAL OF THE INTERCEPT PLASMA SYSTEM

Data Supports Submission for US Regulatory Approval

CONCORD, Calif., and DEERFIELD, Ill., August 17, 2001 - Cerus Corporation (Nasdaq: CERS) and Baxter Healthcare Corporation today reported that the INTERCEPT Plasma System successfully met the primary endpoint of their US Phase IIIb clinical trial. These data further support the safety and therapeutic effectiveness of plasma treated with the INTERCEPT Plasma System, which is being developed to protect against transmission of infectious diseases that may result from plasma transfusions. "These results are significant because they demonstrate that we can offer the pathogen inactivation process with the INTERCEPT Plasma System while maintaining therapeutic performance," said Stephen T. Isaacs, president and chief executive officer of Cerus. "These results will be added to our arsenal of data supporting the safety and efficacy of the INTERCEPT Plasma System, including preclinical studies demonstrating inactivation of a broad spectrum of blood borne pathogens." From: http://www.baxter.com/about_baxter/news_room/news_releases/2001/08-17plasma3.html Nukeh (talk) 01:06, 24 February 2008 (UTC)

Controversy

I really think that this section needs more evidence than a few minutes of footage from an op-ed TV programme. The YouTube clip mentions several investigations conducted by various organisations, including the New York Times; were are these references? I'll have a look around, and see what I can find. MachiavellianMeow 15:49, 20 June 2007 (UTC)

I agree that this is a pretty inflamatory statement that needs more backup. —Preceding unsigned comment added by 68.205.188.74 (talk) 18:17, 7 September 2007 (UTC)

Well, here's a NY times article on the issue:

http://query.nytimes.com/gst/fullpage.html?res=9A00E4DA1F3EF931A15756C0A9659C8B63 I'll add something to the article about this.--140.77.129.149 (talk) 19:55, 16 December 2007 (UTC)

From Baxter's SEC document: On May 6, 1997, the U.S.D.C. approved a class action settlement submitted by the plaintiffs' steering committee for the MDL, Baxter, Alpha Therapeutic Corporation, Armour Pharmaceutical and Bayer Corporation. The essential terms of the settlement provide payments of $100,000 to each HIV-positive person with hemophilia in the United States who can demonstrate use of factor concentrates produced by one of the settling defendants between 1978 and 1985. Additionally, the defendants have established a $40 million fund for payment of attorneys' fees, costs and court-administration expenses. Baxter's agreed contribution to the proposed settlement is 20 percent of the total settlement proceeds. Nukeh (talk) 00:43, 24 February 2008 (UTC)

It appears the Factor 8 harvested from blood was selling for $50 per vial (e.g., pediatric dose). Then the contamination problem was found (HIV, HCB), and the shift over to recombinatant, genetically engineered cells (CHO) was made. The price went to $300 per vial, and it appears that governments with universal health care and /or people without the appropriate insurance could no longer afford Factor 8. This is basically "inside information", and it will take some research to find a reference that does not constitute original research by combining multiple references in a time-course. I stumbled into this area in an attempt to get some Factor 8 to a dying child in Mexico, and I now have a lot of very hostile and defensive email coming in from old buddies in biotech. Nukeh (talk) 13:07, 26 February 2008 (UTC)

Please post any references here for discussion. Is there anything known in terms of cost-benefit ratio? Surely if the procuct is safer it has less knock-on costs in terms of dealing with viral contamination and inhibitors. That would not have helped the Mexican patient in question (was there really no way of getting a compassionate discount?), but would put the pricing in perspective. JFW | T@lk 15:53, 26 February 2008 (UTC)

Is it a protein?

This article is difficult to read for the lay person. Perhaps the article can simply state WHAT Factor VIII is at the beginning (i.e., what type of molecule), instead of just what it does. An article explaining blood clotting factors would also help.FishAmplexity (talk) 14:20, 30 November 2011 (UTC)

Images needs updating

The protein structural image on the main page corresponds to PDB code 1d7p, but this is only a portion of the total structure (specifically the C2 domain). This should be updated with an image for the entire protein such as 2R7E. mattkosloski 13:36, 21 January 2013 (UTC)

I'll leave you a note on your talk page if you need any help doing this. Biosthmors (talk) 20:39, 21 January 2013 (UTC)

I figured it out, but thanks for the push. I've done a lot of research with FVIII and will try to get the time to thoroughly update this article. mattkosloski (talk) 23:08, 21 January 2013 (UTC)